Incyclix Bio
About:
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.
Website: https://incyclixbio.com/
Top Investors: RA Capital Management, Boxer Capital, Eshelman Ventures
Description:
Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers. Founded by Patrick Roberts, Jay Strum, John Bisi, and Fred Eshelman in 2020 and is headquartered in Durham, North Carolina.
Total Funding Amount:
$36M
Headquarters Location:
Durham, North Carolina, United States
Founded Date:
2020-01-01
Contact Email:
info(AT)incyclixbio.com
Founders:
Fred Eshelman, Jay Strum, John Bisi, Patrick Roberts
Number of Employees:
1-10
Last Funding Date:
2022-03-31
IPO Status:
Private
Industries:
© 2025 bioDAO.ai